Relapsed Refractory Lymphoma

Basel, Switzerland, September 17, 2026 Roche has announced positive results from the Phase III CELESTIMO study, showing that a...

IRVINE, California, May 29, 2026 PeproMene Bio, Inc. has announced that updated clinical data from its ongoing Phase 1...